Ionis to present at upcoming virtual investor conferences

Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced its participation in several virtual investor conferences. Management will present at the Wells Fargo Healthcare Conference on September 10, 2020, followed by the Morgan Stanley Global Healthcare Conference on September 14, 2020, the BofA Global Healthcare Conference on September 18, 2020, and the Oppenheimer Life Sciences Summit on September 22, 2020. The presentation details will be available on Ionis' website, with live webcasts and later replays offered. Ionis leads in RNA-targeted drug development.

CARLSBAD, Calif., Sept. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences:

• Wells Fargo 2020 Healthcare Conference on Thursday, September 10, 2020;
• Morgan Stanley 18^th Annual Global Healthcare Conference on Monday, September 14, 2020;
• BofA Global Healthcare Conference on Friday, September 18, 2020; and
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020.

The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-virtual-investor-conferences-301123508.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

What conferences is Ionis Pharmaceuticals presenting at in September 2020?

Ionis Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 10, Morgan Stanley Global Healthcare Conference on September 14, BofA Global Healthcare Conference on September 18, and Oppenheimer Life Sciences Summit on September 22.

Where can I find the live webcast of Ionis Pharmaceuticals' presentations?

The live webcast of Ionis Pharmaceuticals' presentations will be available on their Investors & Media section of the website.

What is Ionis Pharmaceuticals known for in the biotech industry?

Ionis Pharmaceuticals is recognized as a leader in RNA-targeted drug discovery and development, creating therapies for diseases with unmet needs.

How many novel medicines is Ionis Pharmaceuticals developing?

Ionis Pharmaceuticals has a pipeline of more than 40 novel medicines targeting various diseases, including neurological and metabolic conditions.

When will the replays of Ionis Pharmaceuticals' presentations be available?

Replays of Ionis Pharmaceuticals' presentations will be available within 48 hours and archived for a limited time.